Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 3/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.35 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381165 | 0.85 | POLB (0.40) | F10GRM1SMN1; SMN2 | |
| SCHEMBL3377124 | 0.85 | F10 (0.49) | F10GRM1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3378442 | 0.84 | AHR (0.38) | AHRF10GRM1GRM4ALOX15 | |
| SCHEMBL3377538 | 0.84 | AHR (0.45) | AHRF10GRM1GRM4ALOX15 | |
| SCHEMBL3379883 | 0.81 | F10 (0.47) | F10MAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3614270 | 0.79 | PRSS12 (0.44) | F10ALDH1A1HPGDSMN1; SMN2STK33 | |
| SCHEMBL3611444 | 0.78 | NPC1 (0.41) | F10ALOX15HSD17B10ALDH1A1HPGD | |
| SCHEMBL3619322 | 0.77 | FLT1 (0.42) | HSD17B10ALDH1A1HPGDSMN1; SMN2PRSS12 | |
| SCHEMBL3380722 | 0.76 | F10 (0.48) | F10MAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3378168 | 0.76 | F10 (0.63) | F10MAPK1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029586-B1 | ISOINDOLIN-1-ONE-, ISOINDOLIN-3-ONE- AND ISOINDOLIN-1,3-DIONE-DERIVATIVES AND USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | BAYER HEALTHCARE AG (DE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010060-A1 | Isoindolin-1-One-, Isoindolin-3-One- and Isoindolin-1,3-Dione-Derivatives and Use Thereof | ICAM1, SERPINC1, TFPI2 | AHR 1011/4885F10 264/4885GRM1 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.